CNS Response Inc.

George Carpenter is a results-oriented executive with a passion for leading high growth and turnaround companies. As President of CNS Response, Inc., George is leading the commercialization of the company's patented Referenced-EEG technology for psychiatric medication management. Before joining CNS Response Inc., George ran WorkWell Systems Inc., an international physical medicine firm and 2004 winner of the ABL Innovation in Healthcare Award. From 1990 to 2002, George served as Chairman and CEO of CORE, Inc., (Nasdaq: CORE) after leading the management buyout of this division of Baxter Healthcare. A finalist in the E&Y Entrepreneur of the Year program, Carpenter led CORE to a record of clinical software innovation and business development that, in the words of one Wall Street analyst, "created an industry". CORE was acquired in 2001 by Assurant Inc. George was a Vice President of Operations with Baxter Healthcare before founding CORE. His career began at Inland Steel in manufacturing process control and Sales. Serving on various biomedical advisory and fiduciary boards, he is a frequent speaker and writer on healthcare technology and financing issues. His book "The Shape of Things" (LRP Publications, 2006) focused on the neurochemistry of obesity and its impact on the American workforce. He holds an MBA in Finance from the University of Chicago and a BA with Distinction in International Policy & Law from Dartmouth College.

Leonard Brandt co-founded CNS Response (CNSO) of Orange County, CA, in 2000 and is its CEO. In many ways this results from his venture capital investment experience, which taught him of the significant need for technology advancement in mental and addictive medicine. He believes that CNSO will dramatically improve the well being of people suffering from these disorders. Len's prior experience is extensive in new ventures from both venture capital and operating perspectives. As a General Partner at Norwest Ventures he led the fund's investment activity throughout the 1980's in all areas of the healthcare including, biopharmaceutical, healthcare services, medical devices and diagnostics. After that Len turned entrepreneur co-founding Time Segment Publishing and Mill City Ventures Consulting. He co-founded Embro Vascular, the dominant supplier of technology for least-invasive saphenous vein harvesting (heart bypass surgery) now supplied through Boston Scientific (BSX). Len's involvement with an innovative supplier of neurostimulation lead technology, Micronet Medical, (purchased by Advanced Neuromodulation Systems and then St. Jude Medical (STJ)) refocused his attention on CNS analytics and treatment. Len was educated at the University of Illinois and Harvard. He is expanding his education with, Fatherhood 102, a field educational course begun in January 2004 (girl) after successfully completing Fatherhood for Twin Girls 101 on April 6,1999. He is proud to have passed the challenging prerequisite, Husband 101, on April 5, 1997, but his key advisor has suggested he could benefit from an executive educational refresher course. He is an ex-basketball player, ex-skier, ex-autoracer, ex-touring motorcyclist, ex-golfer, and ex-poker player; however, he is known to still masquerade as a squash player.

Daniel Hoffman, MD is a Neuropsychiatrist with over 25 years experience treating general psychiatric conditions such as depression, bipolar disorder and anxiety. He provides the newest advances in diagnosing and treating attentional and learning problems in children and adults. Dr. Hoffman has authored over 40 professional articles, textbook chapters, poster presentations and letters to the editors on various aspects of neuropsychiatry, Quantitative EEG, LORETA, Referenced EEG, advances in medication management, national position papers and standards, Mild Traumatic Brain Injury, neurocognitive effects of Silicone Toxicity, sexual dysfunction and other various topics. Dr. Hoffman has given over 58 major presentations and seminars, including Grand Rounds at Universities and Hospitals, workshops and presentations at national society meeting (such as American Psychiatric Association and American Neuropsychiatric Association), national CME conferences, insurance companies, national professional associations, panel member discussant, and presenter of poster sessions. Dr Hoffman has a Bachelor of Science in Psychology from the University of Michigan, an MD from Wayne State University School of Medicine and conducted his Residency in Psychiatry from the University of Colorado Health Sciences Center.

Prior to receiving his MBA from Wharton in 1990, Brian MacDonald was trained in operations and chemical engineering. He consulted for Deloitte & Touche Management Consulting, KPMG Strategic Services and in private practice. His focus throughout this time was in the area of operations and information systems. He is co-founder of Mill City Venture Development that consulted for the predecessor company to CNS Response. In addition to his work in organizing operations, Mr. MacDonald has led the development of the rEEG automated statistical report generator and the CNS Response managed care economic simulation and analysis software.

Ken Graap is Director of Network Services at CNS Response Inc. As Director of Network Services, Ken develops and oversees outreach and education for professionals interested in applying rEEG? in their professional work. Ken comes to CNS Response after serving as the CEO of Virtually Better, Inc. (Decatur, GA). As CEO, he successfully headed the development and marketing of Virtual Reality systems for use in health and health related applications. Ken received his undergraduate degree in Technical Management with a minor in Economics from Regis University, a Masters degree in Education Psychology from the University of Alberta. He completed 4 years of doctoral work in Clinical Psychology from Emory University and a clinical internship at the Atlanta VA. Ken worked for 5 years at Lexicor Medical Technology, a manufacturer of Quantitative EEG equipment. Ken currently resides in Atlanta, GA with his wife, Kay and their 6 year old daughter, Kyra who is in kindergarten. When not working, he enjoys playing golf, outdoor activities, and traveling.

Array

Max Schneider, MD, Director of Education, Positive Action Center at Chapman Medical Center, Orange, California, is a Fellow and Past President of the American Society of Addiction Medicine (ASAM), a Past Chair of the Board of Directors of the National Council on Alcoholism and Drug Dependence (NCADD), a former consultant to the Drug and Alcohol Advisory Committee of the U.S. Food and Drug Administration and a Certified Medical Review Officer. He currently serves as a Clinical Professor at the University of California at Irvine where he teaches in their Addiction Medicine program which he founded in 1969. Dr. Schneider has produced ten films and five booklets on addiction, In 1956 he was a member of the research team that developed "mouth to mouth" resuscitation that revolutionized the technique of artificial resuscitation. He has received 42 different awards, primarily for his contributions to addiction medicine.

The second speaker, Maurizio Fava, M.D., a 1994 NARSAD Young Investigator, is professor of psychiatry at Harvard Medical School and director of the Depression Clinical and Research Program at Massachusetts General Hospital, where he is also associate chief of psychiatry for clinical research and a founding member of the Mood and Anxiety Disorders Institute. In his talk, he reviewed findings that have been emerging from the National Institute of Mental Health's Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, of which he is a co-principal investigator. Begun in 1999, STAR*D is the largest study of depression treatment ever conducted, involving 14 regional centers and a total of 41 clinical sites. Dr. Fava described the 2,876 participants as a real-world representation of depression patients in terms of sex, ethnicity, mean age, age of onset of illness, rate of recurrence and associated conditions, such as anxiety, hypertension and diabetes.